Table 11-1.
Antimicrobial and Antifungal Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Amikacin | 8-16 mg/kg SC, IM, IV divided q8-24h53 | Potentially ototoxic and nephrotoxic |
10-15 mg/kg SC, IM q12h52 | ||
Amoxicillin | 20 mg/kg PO, SC q12h52 | |
30 mg/kg PO q8h × 21 days16 | Helicobacter; can use with metronidazole and bismuth subsalicylate | |
Amoxicillin/clavulanic acid (Clavamox, Zoetis) | 13-25 mg/kg PO q8-12h52 | |
18.75 mg per jill PO q12h15 | For treatment of E. coli induced mastitis | |
Amphotericin B | 0.15 mg/kg IV 3×/wk × 2-4 mon25 | Treatment of cryptococcosis |
0.25-1 mg/kg IV q24h or q48h until total dose of 7-25 mg has been given25 | ||
0.4-0.8 mg/kg IV q7d52 | Blastomycosis; monitor for azotemia; total dose 7-25 mg | |
Ampicillin | 5-30 mg/kg SC, IM, IV q8-12h51,52 | |
Azithromycin | 5 mg/kg PO q24h60 | |
Cefadroxil | 15-20 mg/kg PO q12h52 | |
Cefovecin (Convenia, Zoetis) | 8 mg/kg SC q2-3d49 | Second generation parenteral cephalosporin; long-acting antibiotic |
Cephalexin | 15-30 mg/kg PO q8-12h53 | |
Cephaloridine | 10-25 mg/kg SC, IM q24h × 5-7 days53 | Dermatitis |
Chloramphenicol | 25-50 mg/kg PO, SC, IM, IV q12h53 | 14-day minimum for proliferative bowel disease |
50 mg/kg SC, IM q12h15 | For treatment of mastitis | |
Ciprofloxacin | 10-30 mg/kg PO q24h53 | Mix 500 mg tablet in 10 mL water (50 mg/mL); flavor for improved acceptance |
Clarithromycin | 12.5 mg/kg PO q8-12h × 14 days44 | Helicobacter; use with ranitidine bismuth citrate |
50 mg/kg PO q24h or divided q12h × 14 days51 | Helicobacter; use with omeprazole (or ranitidine) and metronidazole | |
Clindamycin | 5.5-10 mg/kg PO q12h53 | Anaerobic infections; bone and dental disease |
12.5 mg/kg PO q12h53 | Toxoplasmosis | |
Cloxacillin | 10 mg/kg PO, IM, IV q6h65 | |
Doxycycline | 10 mg/kg PO q12h37 | May help with ferret systemic coronavirus infection |
Enrofloxacin (Baytril, Bayer) | 5 mg/kg PO, IM q12h15 | For treatment of mastitis |
5-10 mg/kg PO, SC, IM q12h53 | IM for short term (generally 1 injection); injectable form can be given PO in palatable liquid; liquid for PO can also be compounded | |
10-20 mg/kg PO, SC, IM q12-24h52 | ||
Erythromycin | 10 mg/kg PO q6h52 | |
220 g/ton feed53 | Controlling Campylobacter diarrhea in large groups | |
Fluconazole | 50 mg/kg PO q12h53 | |
Gentamicin | 2 mg/kg PO q12h × 10-14 days21 | Parenteral form can be given PO; proliferative colitis that is nonresponsive to chloramphenicol12,21 |
2-5 mg/kg SC, IM, IV q12-24h52 | If given IV, dilute with saline and administer over 20 min | |
Griseofulvin | 25 mg/kg PO q12-24h53 | Refractory dermatomycosis; use with lime-sulfur dips q7d |
Itraconazole | 1.5 mg/kg PO q24h41 | Invasive nasal cryptococcosis |
10 mg/kg PO q12h20 | Histoplasmosis | |
10-20 mg/kg PO q24h67 | Cryptococcosis | |
25-33 mg/kg PO q24h25,72 | ||
Ketoconazole | 10-50 mg/kg PO q12-24h39 | |
Lime sulfur | Dip q7d52 | Dermatomycosis; see griseofulvin |
Lincomycin | 11 mg/kg PO q8h53 | |
Metronidazole | 15-20 mg/kg PO q12h52 | Anaerobic infections; can use with amoxicillin and bismuth subsalicylate for Helicobacter |
Neomycin | 10-20 mg/kg PO q6h52 | Potential nephrotoxicity and neuromuscular blockage |
Netilmicin (Netromycin, Schering) | 6-8 mg/kg SC, IM, IV q24h53 | Severe staphylococcal infections |
Nitazoxanide (Alinia, Romark Laboratories) | 5 mg/kg PO q12h25 | Treatment of cryptosporidiosis |
Oxytetracycline | 20 mg/kg PO q8h52 | |
Penicillin G (sodium or potassium) | 20,000 U/kg IM q12h39 40,000 U/kg SC, IM q24h52 |
|
Pentamidine isethionate | 3-4 mg/kg SC q48h25 | Pneumocystis pneumonia |
Pyremethamine | 0.5 mg/kg PO q12h25 | Combine with trimethoprim sulfa (30 mg/kg PO q12h) and folic acid (3-5 mg/kg PO q24h) for treatment of toxoplasmosis |
Sulfadimethoxine | 25 mg/kg PO, SC, IM q24h53 | |
30-50 mg/kg PO q12-24h52 | ||
Sulfamethazine | 1-5 mg/mL drinking water52 | |
Sulfasoxazole | 50 mg/kg PO q8h53 | |
Sulfathalidine | Mix in food at dose of 1 g/day/kg body weight12 | Opioid useful for management of Salmonella and to reduce shedding in colonies |
Tetracycline | 20-25 mg/kg PO q8-12h52 | |
Trimethoprim/sulfa | 5 mg/kg PO q24h15 | Pyelonephritis |
15 mg/kg IV q12h8 | ||
15-30 mg/kg PO, SC q12h52 | Dosage amount of combined drugs | |
Tylosin (Tylan, Elanco) | 5-10 mg/kg PO, SC, IM, IV q12h51,52 |
Table 11-2.
Antiparasitic Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Amitraz (Mitaban, Upjohn) | 0.0125% topical solution q7d × 3 treatments, then 0.0375% q7d × 3 treatments52 | Demodecosis secondary to other illness |
0.03% topical solution to affected area q7d × 3-6 treatments53 | Demodecosis; use full concentration | |
Amprolium | 19 mg/kg PO q24h52 | Coccidiosis |
100 mg/kg PO in food or water for 7 days25 | Isospora | |
Carbaryl powder (5%) | Topical q7d × 3-6 treatments52 | Ectoparasites |
Decoquinate | 0.5 mg/kg PO for at least 2 wk60 | Coccidiosis; larger groups of ferrets |
Fenbendazole | 20 mg/kg PO q24h × 5 days52 | |
50 mg/kg PO q24h × 30 days52 | Mesocestoides infection | |
Fipronil (Frontline, Merial) | 1 pump of spray or ⅕-½ of cat pipette topical q60d52 | Flea adulticide |
0.2-0.4 mL topically q30d52 | ||
Imidacloprid (Advantage, Bayer) | 10 mg/kg topically36 | Flea treatment; PD |
0.1-0.4 mL topically q30d39,52 | Flea adulticide; use small cat/kitten vial | |
Imidacloprid/moxidectin (Advantage Multi, Bayer) | 1.9-3.3 μg/kg topically q30d60 | Heartworm prevention |
Ivermectin | 0.02 mg/kg PO, SC q30d69 | Heartworm prevention |
0.05 mg/kg PO q30d until negative testing69 | Recommended treatment for heartworms; give prednisolone (1 mg/kg/day) concurrently | |
0.05-0.3 mg/kg PO q24h for 1 mo after negative skin scraping6 | Demodecosis | |
0.2-0.5 mg/kg SC q14d × 3 treatments52 | Sarcoptic mange | |
0.4 mg/kg PO, SC, repeat in 14-28 days52 | Ear mites, ticks | |
0.5-1 mg/kg in ears, repeat in 14 days52 | Ear mites; half dose in each ear; treat cats and dogs in house concurrently | |
Lime sulfur | Dip 1:40 dilution q7d × 6 wk21 | Demodectic mange |
Lufenuron (Program, Novartis) | 10 mg/kg SC25 | Flea larvicide |
30 mg/kg PO in food25 | ||
30-45 mg/kg PO q30d52 | ||
Mebendazole | 50 mg/kg PO q12h × 2 days25 | Nematodes |
Melarsomine dihydrochloride (Immiticide, Merial) | 2.5 mg/kg IM once, repeat in 30 days with 2 treatments 24 hr apart52 | Heartworm adulticide; less commonly used; use prednisone (1 mg/kg q24h × 4 mo) following treatment |
Metronidazole | 15-20 mg/kg PO q12h × 14 days52 | Gastrointestinal protozoa |
Milbemycin oxime (Interceptor, Novartis) | 1.15-2.33 mg/kg PO q30d52 | Heartworm preventive |
Moxidectin | 0.17 mg SC once60 | Heartworm adulticide |
Paromomycin | 165 mg/kg PO q12h × 5 days60 | Cryptosporidiosis; possible treatment; use with caution, severe renal disease possible |
Piperazine citrate | 50-100 mg/kg PO q14d53 | Intestinal nematodes |
Praziquantel (Droncit, Bayer) | 5-10 mg/kg PO, SC, repeat in 1053-14d52 | Cestodes |
25 mg/kg PO × 3 days60 | Trematodes | |
Pyrantel pamoate | 4.4 mg/kg PO, repeat in 14 days52 | |
Pyrethrins | Topical q7d prn52 | Fleas; use products safe for puppies and kittens |
Pyrimethamine | 0.5 mg/kg PO q12h25 | Toxoplasmosis; antiprotozoal |
Selamectin (Revolution, Zoetis) | 6-18 mg/kg topically51, 52, 53,60 | Ectoparasites (fleas, lice, most mites except Demodex) |
15 mg topically q30d14 | Ear mites, fleas; PD | |
45 mg/ferret topically50 | Ear mites; although this dose has been reported in a PD study, it appears that lower (safer?) doses (see previous) are also quite effective | |
Sulfadimethoxine | 20-50 mg/kg PO q24h7 | Coccidia |
50 mg/kg PO, then 25 mg/kg q24h × 9 days52 | ||
0.5 mL/kg of a 12.5% solution mixed into drinking water56 | For treatment of enteric coccidiosis in a large group of ferrets | |
Thiabendazole/dex-amethasone/neomycin (Tresaderm, Merial) | 2 drops in each ear q24h × 7 days, off 7 days, on 7 days55 | Ear mites |
Table 11-3.
Chemical Restraint/Anesthetic Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Acepromazine | — | See ketamine for combination |
0.1-0.25 mg/kg SC, IM52 | Preanesthetic; light sedation | |
0.1-0.5 mg/kg SC, IM33 | Rapid onset of sedation if given IM; doses above 0.2 mg/kg are associated with prolonged recovery times and hypothermia | |
0.2-0.5 mg/kg SC, IM52 | Tranquilization | |
Alfaxalone (Alfaxan, Jurox) | 5 mg/kg IV18 | Anesthetic induction; PD |
5-15 mg/kg IM28 | Sedative | |
Atipamezole (Antisedan, Zoetis) | 0.4 mg/kg IM53 1 mg/kg SC, IV, IP52 |
Dexmedetomidine and medetomidine reversal; give same volume SC, IV, IP as medetomidine or dexmedetomidine (5 × medetomidine or 10 × dexmedetomidine dose in mg) |
Atropine | 0.04-0.05 mg/kg SC, IM, IV52 | Preanesthetic; bradycardia; hypersalivation |
Bupivacaine | 1 mg/kg epidurally52 | Epidural anesthesia; analgesia |
1-1.5 mg/kg SC infiltrate27 | Local anesthesia; lasts several hours | |
Butorphanol | Loading dose 0.05-0.2 mg/kg; maintenance 0.1-0.4 mg/kg/hr21 | Constant-rate infusion (CRI) for perioperative analgesia; see ketamine, midazolam, and tiletamine/zolazepam for combinations |
Dexmedetomidine (Dexdomitor, Zoetis) | 0.04-0.1 mg/kg IM49 | α2 agonist similar to medetomidine; not commonly used because of bradycardia and other side effects |
Diazepam | — | See ketamine for combinations; drug is slowly and incompletely absorbed following IM administration |
0.5 mg/kg PO, IM, IV q6-8 h59 | Smooth muscle relaxation in urethral obstruction cases | |
0.5-1.5 mg/kg/h constant-rate infusion3 | Seizure control | |
1 mg/animal IV52 | Seizure control; 1-2 boluses | |
2 mg/kg SC, IM25 | Tranquilization; seizure control | |
Enflurane | 2% maintenance52 | Anesthesia |
Etomidate | 1 mg/kg IV27 | Induction and intubation of critically ill animal |
Fentanyl citrate/fluanisone (Hypnorm, Janssen) | 0.3 mg/kg IM52 | Anesthesia; not available in the United States |
Fentanyl/droperidol (Innovar-Vet, Schering Plough) | 0.15 mL/kg IM52 | Minor surgical procedures; deep sedation |
Glycopyrrolate | 0.01 mg/kg IM52 | Preanesthetic; bradycardia; hypersalivation |
Isoflurane | To effect32 | Inhalant anesthesia |
Ketamine | — | Ketamine combinations follow |
10-20 mg/kg IM52 | Tranquilization; induction | |
30-60 mg/kg IM52 | Anesthesia; when used alone, high doses cause poor muscle relaxation, rough recoveries, and convulsions; not recommended as a sole agent | |
Ketamine (K)/acepromazine (A) | (K) 20-35 mg/kg + (A) 0.2-0.35 mg/kg SC, IM52 | Anesthesia |
Ketamine (K)/diazepam (D) | (K) 10-20 mg/kg + (D) 1-2 mg/kg IM52 | Anesthesia; poor analgesia61 |
0.1 mL/kg IV52 | Induction; will allow intubation with premedication; use equal volumes of (K) at 100 mg/mL and (D) at 5 mg/mL | |
Ketamine (K)/dexmedetomidine (D) | (K) 5 mg/kg IM + (D) 0.03 mg/kg IM52 | Medetomidine no longer commercially available; dexmedetomidine at half the dose of medetomidine may be effective |
Ketamine (K)/medetomidine (M) or dexmedetomidine (D)/butorphanol (B) | (K) 5 mg/kg + (M) 0.08 mg/kg or (D) 0.04 mg/kg + (B) 0.2 mg/kg IM32 | Medetomidine no longer commercially available; induction or total injectable anesthesia; allows for intubation; 60-80 min of surgical plane of anesthesia |
Ketamine (K)/midazolam (M) | (K) 5-10 mg/kg + (M) 0.25-0.5 mg/kg IV51 | |
0.1 mL/kg IV52 | Induction; use equal volumes of (K) at 100 mg/mL and (M) at 5 mg/mL | |
Ketamine (K)/xylazine (X) | (K) 10-25 mg/kg + (X) 1-2 mg/kg IM52 | Anesthesia; avoid in sick animals;39 may result in cardiac arrhythmias61 |
Lidocaine | 1-2 mg/kg total SC27 | Local anesthesia; use 1%-2% solution; lasts 15-30 min |
0.5-1.0 mg/kg IV q12h52 | ||
Midazolam (Versed, Roche) | — | See ketamine for combination; can be reversed with flumazenil at same volume |
0.25-0.3 mg/kg SC, IM25 | Mild sedation; premedication | |
0.25-0.5 mg/kg SC, IM, IV53 | ||
Midazolam (M)/butorphanol (B) | (M) 0.2 mg/kg + (B) 0.2 mg/kg IM10,58 | Good sedation; premedication for minor procedures (i.e., ultrasonography, endoscopy, etc.); if needed, can follow with gas anesthesia or IV propofol; can reverse midazolam with flumazenil |
Naloxone (Narcan, Dupont) | 0.01-0.03 mg/kg IM, IV52 0.04 mg/kg SC, IM, IV52 |
Reversal of opioids; up to 1 mg/kg may be used |
Propofol | 1-3 mg/kg IV32 | Induction when premedicants are used; bradypnea or apnea and hypoxia common; intubation and oxygen insufflation is recommended |
2-10 mg/kg IV25 | Induction | |
Sevoflurane | To effect51 | Inhalant anesthesia |
Tiletamine/zolazepam (Telazol, Fort Dodge) | — | Tiletamine/zolazepam combinations follow |
12-22 mg/kg IM52 | Minor surgical procedures at 22 mg/kg; recovery may be prolonged at higher doses; poor muscle relaxation; rarely indicated | |
Tiletamine/zolazepam (T)/xylazine (X) | 3 mg/kg (T) + 3 mg/kg (X) IM34 | Small injection volume; rapid and smooth induction; allows for endotracheal intubation |
Tiletamine/zolazepam (T)/xylazine (X)/butorphanol (B) | 1.5 mg/kg (T) + 1.5 mg/kg (X) + 0.2 mg/kg (B)34 | Small injection volume; rapid and smooth induction; allows for endotracheal intubation; analgesia; profound cardiorespiratory depression necessitates oxygen insufflation |
Tiletamine/zolazepam (T)/dexmedetomidine (D)/butorphanol (B) | 0.03 mL/kg IM of prepared solution (see comment)32 | Telazol powder is reconstituted with 2.5 mL of dexmedetomidine and 2.5 mL of butorphanol (10 mg/mL) to form final volume of 5 mL |
Xylazine | — | See ketamine and tiletamine/zolazepam for combinations |
0.1-0.5 mg/kg SC, IM53 | Tranquilization; may cause hypotension, bradycardia, and arrhythmias; use with care in sick animals | |
2 mg/kg IM33 | Rapid immobilization within 3-5 minutes; associated with arrhythmias, hypotension, bradycardia | |
Yohimbine (Yobine, Lloyd) | 0.2-0.5 mg/kg IV52 | Xylazine reversal |
0.5-1 mg/kg IM52,53 |
Table 11-4.
Analgesic Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Acetylsalicylic acid (aspirin) | 0.5-22 mg/kg PO q8-24h52 | Analgesia; antiinflammatory; antipyretic; cannot be compounded as molecule is unstable in aqueous solution |
Amantadine | 3-5 mg/kg PO49 | May potentiate other analgesics via NMDA antagonist action |
Bupivicaine | 1-2 mg/kg SC32 | |
Buprenorphine | 12 μg/kg epidurally21 | Epidural analgesia/anesthesia |
0.04 mg/kg IM q4-6h29 | PK | |
0.01-0.05 mg/kg oral transmucosal, SC, IM, IV q6-12h32,52 | Analgesia | |
Butorphanol | — | See ketamine, midazolam, and tiletamine/zolazepam (see Table 11-3) for anesthetic combinations |
0.05-0.5 mg/kg SC, IM q8-12h32,52 | Analgesia; lower end of dose may be too low for clinical effect; higher end of dose range may cause profound sedation | |
0.3 mg/kg SC q2-4h29 | PK | |
Carprofen (Rimadyl, Zoetis) | 1-5 mg/kg PO q12-24h21,52 | Nonsteroidal antiinflammatory; use caution in animals with gastritis or enteritis |
4 mg/kg SC32 | ||
Fentanyl citrate | 1.25-5 μg/kg/h IV via constant-rate infusion21,49 | Postoperative analgesia |
10-30 μg/kg/h IV via constant-rate infusion21,49 | Perioperative analgesia; administer after loading dose of 5-10 μg/kg IV | |
Flunixin meglumine (Banamine, Schering) | 0.3-2 mg/kg IV, PO, SC q12-24h52,53 |
Nonsteroidal antiinflammatory; use caution in animals with gastritis or enteritis; use caution in using drug more than 5 days continuously; mix injectable form with palatable syrup for PO |
2.5 mg IM q12h14 | ||
Gabapentin | 3-5 mg/kg PO q8-24h52 | Neurotropic pain; may cause sedation at higher doses |
Hydromorphone | 0.1 mg/kg SC q1-2h29 | Opioid; PK |
0.1-0.2 mg/kg SC, IM, IV39 | ||
Ibuprofen | 1 mg/kg PO q12-24h51 | Nonsteroidal antiinflammatory |
Ketamine | 0.1-0.4 mg/kg/h IV via constant-rate infusion21 | Postoperative analgesia |
0.3-1.2 mg/kg/h IV via constant-rate infusion21 | Perioperative analgesia; administer after 2-5 mg/kg IV loading dose | |
Ketoprofen (Ketofen, Fort Dodge) | 1-3 mg/kg PO, SC, IM q24h53 | Nonsteroidal antiinflammatory; use caution with gastritis or enteritis or if using > 5 days |
Meloxicam | 0.1-0.3 mg/kg PO, SC, IM q24h24,25,27 | Nonsteroidal antiinflammatory; monitor liver and kidney values |
Meperidine (Demerol, Winthrop-Breon) | 5-10 mg/kg SC, IM, IV q2-4h25 | Analgesia |
Morphine | 0.1 mg/kg epidurally21 | Analgesia |
0.2-5 mg/kg SC, IM q2-6h52 | SC administration of 1 mg/kg associated with emesis, excitability, and ptyalism39 | |
Nalbuphine (Nubain, Endo Labs) | 0.5-1.5 mg/kg IM, IV q2-3h25 | Analgesia |
Oxymorphone | 0.05-0.2 mg/kg SC, IM, IV q8-12 h27,52 |
Analgesia |
Pentazocine (Talwin, Sanofi Winthrop) | 5-10 mg/kg IM q4h52 | Analgesia |
Tramadol | 5-10 mg/kg PO q12-2425 | Analgesia; synergistic with NSAIDs |
Table 11-5.
Cardiopulmonary Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Aminophylline | 4-6.6 mg/kg PO, IM, IV q12h52 | Bronchodilator |
Amlodipine (Norvasc, Pfizer) | 0.2-0.4 mg/kg PO q12h28 | Vasodilator |
Atenolol (Tenormin, ICI) | 3.125-6.25 mg/kg PO q24h35,52 6.25 mg/animal PO q24h52 |
β-adrenergic blocker for hypertrophic cardiomyopathy |
Atropine | 0.02-0.04 mg/kg SC, IM52 | Bradycardia |
0.1 mg/kg intratracheal52 | ||
Benazepril | 0.25-0.5 mg/kg PO q24h35,68 | Vasodilator; less nephrotoxic than enalapril |
Captopril (Capoten, Squibb) | of 12.5 mg tablet/animal PO q48h52 | Vasodilator; starting dose, gradually increase to q12-24h; can cause lethargy |
Digoxin (Cardoxin, Evsco) | 0.005-0.01 mg/kg PO q12-24h52 | Positive inotrope for dilated cardiomyopathy; monitor serum levels |
Diltiazem (Cardizem, Marion Merrill Dow) | 1.5-7.5 mg/kg PO q12h35,52 | Calcium channel blocker for hypertrophic cardiomyopathy |
Dobutamine | 0.01 mL/animal IV prn28 | Hypotension |
Doxapram | 1-2 mg/kg IV52 | Respiratory stimulant |
5-11 mg/kg IV52 | ||
Enalapril (Enacard, Merck) | 0.25-0.5 mg/kg PO q24-48h35,52 | Vasodilator for dilated cardiomyopathy; do not use with concurrent renal disease |
Epinephrine | 0.02 mg/kg SC, IM, IV, intratracheal43 | Cardiac arrest; anaphylactic reactions (including vaccine reactions) |
0.2 mg/kg IV, intracardiac, IO25 | ||
0.2-0.4 mg/kg diluted in 0.9% NaCl25 intratracheal | Administer during cardiopulmonary arrest | |
Furosemide | 1-4 mg/kg PO, SC, IM, IV q8-12h52 | Diuretic; use high dose in fulminant heart failure |
2-3 mg/kg IM, IV q8-12h followed by 1-2 mg/kg PO q12h for long-term management69 | Emergency management of fulminant heart failure | |
Hyperimmune serum | 1 mL/animal IV once57 | Use serum from a healthy, appropriately vaccinated ferret for treatment of canine distemper virus infection |
Isoproterenol | 20-25 μg/animal SC, IM q4-6h69 40-50 μg/animal PO q4-6h69 |
Positive chronotrope to increase ventricular rate in third-degree AV block |
Metaproterenol | 0.25-1 mg/kg PO q12h69 | Positive chronotrope to increase ventricular rate in third-degree AV block |
Nitroglycerin (2%) ointment (Nitrol, Savage) | - inch/animal q12-24h52 | Vasodilator for cardiomyopathy; apply to shaved inner thigh or pinna |
Pimobendan | 0.25-1.25 mg/kg PO q12h25 0.5 mg/kg PO q12h69 0.625-1.25 mg/kg q12h39 |
Phosphodiesterase inhibitor; increases cardiac contractility with dilated cardiomyopathy or mitral valve disease |
Propranolol (Inderal, Wyeth-Ayerst) | 0.2-1 mg/kg PO q8-12h52 2 mg/kg PO, SC q12h52 |
β-blocker for hypertrophic cardiomyopathy; may cause lethargy, loss of appetite |
Pseudophedrine | 5 mg/kg PO q8h69 | Positive chronotrope to increase ventricular rate in third-degree AV block |
Terbutaline | 2.5-5 mg/kg PO q12-24h27 | Bronchodilator |
Theophylline | 4.25 mg/kg PO q8-12h12 | Bronchodilator; use elixir |
Table 11-6.
Adrenal Gland Disease Agents Used in Ferrets.
Agent | Dosage | Comments |
---|---|---|
Anastrazole (Arimidex, Astrazeneca Pharmaceuticals) | 0.1 mg/kg PO q24h52 | Estrogen inhibitor; precursor hormones blocked by inhibition of aromatase enzyme; use until signs resolve, then 7 days on, 7 days off, etc.; pregnant owners should avoid handling agent |
Bicalutamide (Casodex, Astrazeneca Pharmaceuticals) | 5 mg/kg PO q24h52 | Testosterone inhibitor; competitively inhibits androgen by binding to receptors in target tissues; use until clinical signs resolve, then 7 days on, 7 days off, etc.; pregnant owners should avoid handling agent |
Deoxycorticosterone pivalate (DOCP) | 2 mg/kg IM q21d52 | Treatment of adrenal insufficiency following bilateral adrenalectomy |
Deslorelin (Suprelorin, Virbac Animal Health) | — | Long-acting GnRH analog that may suppress LH and FSH; used to control signs of adrenal disease; given as a subcutaneous implant approximately once yearly; now available in the United States |
2.7 mg implant SC38 | Alternative to spay/neuter; the 2.7 mg implant is not available in the United States | |
3 mg or 4.7 mg SC38,71 | The 3 mg implant is not available in the United States | |
4.7 mg implant SC25 | Treatment of adrenal disease; lasts 10-18 months | |
9.4 mg implant SC25 | Treatment of adrenal disease; lasts 16-48 months; not available in the United States | |
Finasteride (Proscar, Merck) | 5 mg/kg PO q24h52 | Inhibits conversion of testosterone to active form of dihydrotestosterone; also used in treatment of prostatic enlargement |
Flutamide (Eulexin, Schering) | 5-10 mg/kg PO q12-24h11,52,63 | Androgen inhibitor; reduces enlarged periurethral prostate tissue; lifetime treatment; associated with mammary tumors |
Leuprolide acetate (Lupron, AbbVie) | — | Long-acting GnRH analog that may cause an initial stimulation, then suppression of LH and FSH; palliative treatment of adrenal disease (will not resolve tumor); administer q28d until clinical signs regress, then treatment interval can be up to 6-8 wk; lifetime treatment; higher dosage may shrink prostate within 12-48 hr which may improve urine flow in cases of urethral obstruction; must be prepared in aliquots and frozen (although the effects of freezing on drug efficacy are questionable) until used; very expensive |
1 mg IM q60-75d11 3 month depot |
Adrenal disease | |
Lupron, Depot 30 day (TAP) | 100-150 μg/kg IM q4-8wk1,70 250 μg/kg IM q4-8wk26 |
|
Lupron, Depot 4 month (TAP) | 250 μg/kg IM59 2 mg/kg SC, IM q16wk52 |
|
Melatonin | 0.5-1 mg/animal PO q24h61 prn | Symptomatic treatment of hyperadrenocorticism; may not affect tumor growth |
5.4 mg implant SC52 | Should last 6-12 mo | |
Mitotane (o,p′-DDD) (Lysodren, Bristol-Myers) | — | Hyperadrenocorticism; variable results and not a reliable alternative to adrenalectomy or other drugs mentioned above; results have been largely unsatisfactory and, therefore, use is not recommended |
Trilostane (Vetoryl, Dechra) | 2 mg/kg PO q12h52 | May be useful for treating pituitary-dependent hyperadrenocorticism or adrenal dependent hyperadrenocorticism; reduces synthesis of adrenal androgens |
Table 11-7.
Miscellaneous Agents Used in Ferrets.a
Agent | Dosage | Comments |
---|---|---|
Activated charcoal | 1-3 g/kg PO52 | Orally administered adsorbent for gastrointestinal tract toxins/drug overdoses |
Amantadine (Symmetrel, Endo Labs) | 6 mg/kg as aerosol q12h5,25,52 | Influenza; experimental antiviral |
Apomorphine | 0.7 mg/kg SC52 | Emetic |
5 mg/kg SC52 | Emetic; may cause excitation | |
Atropine | 5-10 mg/kg SC, IM52 | Organophosphate toxicity |
Azathioprine (Imuran, GlaxoSmithKline) | 0.9 mg/kg PO q24-72h9 | Immunosuppressive agent; may use in chronic hepatitis |
Barium (30%) | 8-13 mL/kg PO52 | Gastrointestinal contrast study |
Barium (60%) | 17 mL/kg PO66 | Followed 30 minutes later by 42 mL/kg of air for a double contrast gastrointestinal study |
Bismuth subcitrate, colloidal | 6 mg/kg PO q12h52 | In combination with enrofloxacin at 4.25 mg/kg q12h for Helicobacter |
Bismuth subsalicylate (Pepto-Bismol, Procter & Gamble) | 0.25-1 mL/kg PO q4-8h52 | Gastrointestinal ulcers; may help prevent Helicobacter colonization |
17.5 mg/kg PO q8-12h52 | ||
Bleomycin (Blenoxane, BristolMyersSquibb) | 10 U/m2 SC52 | Treatment of squamous cell carcinoma |
Budesonide (Entocort, Astrazenca) | Up to 1 mg/ferret PO q24h49 | Novel steroid may have use as single agent treatment for inflammatory bowel disease |
Cabergoline | 5 μg/kg PO q24h × 5 days27 | Pseudopregnancy |
Calcium EDTA | 20-30 mg/kg SC q12h62 | Treatment of heavy metal toxicosis |
Chitosan | 0.5 mg/kg on food q12h49 | Intestinal phosphorus and uremic toxin absorbent; cellulose-like biopolymer from exoskeletons of marine invertebrates |
Chlorambucil (Leukeran, Glaxo) | 1 mg/kg PO4 20 mg/m2 PO52 |
Antineoplastic; in chemotherapy protocols for lymphomaa |
Chlorpheniramine (Chlor-Trimeton, Squibb) | 1-2 mg/kg PO q8-12h52 | Antihistamine; control sneezing and coughing when they interfere with eating or sleeping |
Cimetidine (Tagamet, SmithKline) | 5-10 mg/kg PO, SC, IM q8h52 10 mg/kg PO, IV q8h25 |
H2 blocker; inhibits acid secretion; gastrointestinal ulcers; unpalatable; give IV (slow) |
Ciproheptadine (Periactin, Merck) | 0.5 mg/kg PO q12h49 | Appetite stimulation |
Cisapride (Propulsid, Janssen) | 0.5 mg/kg PO q8-12h52 | Antiemetic; motility enhancer; not currently available in the United States; must be compounded |
Cobalamin | 25 μg/kg SC q7d × 6 wk, then q14d × 6 wk, then q30d24 | Chronic diarrhea; with cobalamin malabsorption |
Cyclophosphamide | 10 mg/kg PO, SC52 | Antineoplastic; use at higher dose for salvage treatment of lymphomaa |
200 mg/m2 PO, SC4 | ||
250 mg/m2 PO q4-5wk47 | Part of a noninvasive protocol for treatment of lymphomaa | |
Cyclosporine | 4-6 mg/kg PO q12h42 | Pure red cell aplasia |
Cytarabine (Cytosar-U, Zoetis) | 300 mg/m2 q8wk47 | Part of a noninvasive protocol for treatment of lymphomaa |
Dexamethasone | 0.5 mg/kg SC, IM, IV52 | |
1 mg/kg IM52 | Post-adrenalectomy; follow with prednisone | |
Dexamethasone sodium phosphate | 1-2 mg/kg IV3 | Cerebral edema therapy |
2 mg/kg IM, IV19 | Anaphylactic reaction to vaccine | |
4-8 mg/kg IM, IV52 | Shock therapy | |
Dextrose 50% | 0.25-2 mL IV40 | Bolus for hypoglycemia; give to effect |
1.25%-5% IV40 | Infusion for hypoglycemic or inappetant animal | |
Diazoxide (Proglycem, Medical Market Specialties) | 5-30 mg/kg PO q12h45,52 10 mg/kg PO q24h or divided q8-12h52 |
Insulinoma; insulin-blocker; can cause hypertension, lethargy, depression, nausea |
Diphenhydramine | 0.5-2 mg/kg PO, IM, IV q8-12h43,52 |
Antihistamine; controls sneezing and coughing when they interfere with eating or sleeping; give at high dose IM prevaccination when previous reaction occurred or for treatment of vaccine reaction |
Doxapram | 1-2 mg/kg IV52 | Respiratory stimulant |
2-5 mg/kg IV53 | ||
Doxorubicin | 1 mg/kg IV q21d × 4 treatments4 | Antineoplastic agent; lymphoma;a salvage treatment |
Epinephrine | 0.02 mg/kg SC, IM, IV, IT52 | Severe vaccine reaction; cardiac arrest |
Epoetin alfa (Epogen, Amgen) | 50-150 U/kg PO, IM q48h52 | Stimulates erythropoiesis; after desired PCV is reached, administer q7d for maintenance |
Famotidine (Pepcid, Merck) | 0.25-0.5 mg/kg PO, SC, IV q24h52 | Inhibits acid secretion; gastrointestinal ulcers |
2.5 mg PO, SC, IV q24h25 | ||
Fludrocortisone (Florinef, SquibbMark) | 0.05-0.1 mg/kg PO q24h or divided q12h52 | Mineralocorticoid replacement after adrenal gland removal |
Flunixin meglumine (Banamine, Schering) | 1 mg/kg SC, IM52 | Prevention of prostaglandin-mediated hypotension of endotoxemia |
2.5 mg/animal SC, IM q12h prn14 | Reduce inflammation in mastitis | |
Flurbiprofen sodium | 1-2 drops q12-24h25 | Ophthalmic inflammation |
Gadolinium-diethylenetriamine pentaacetic acid (GI-DPTA) (Omniscan, GE Healthcare) | 0.2 mL/kg3 | MRI contrast agent for neurological studies |
Glucagon | 15 ng/kg/min IV constant-rate infusion8 | Emergency management of hypoglycemia secondary to insulinoma |
Glutamine | __ | Amino acid; L form available OTC as a nutritional supplement; improves immune system, digestive health, and enhances muscle production |
0.5 g/kg PO divided daily49 | Enterocyte supplementation with starvation | |
Gonadotropin-releasing hormone (GnRH) (Cystorelin, Sanofi) | 20 μg/animal IM14 | Termination of estrus after day 10 of estrus; repeat in 2 wk prn |
Hairball laxative, feline | 1-2 mL/animal PO q48h52 | Trichobezoar prophylaxis |
Heparin | 100 U/animal (0.45-1.35 kg) SC q24h × 21 days35 | May be used in some heartworm treatments |
200 U/kg SC, IM q12h × 5 days52 | Decreases thromboembolism; start day prior to some heartworm adulticide treatments | |
Human chorionic gonadotropin (hCG) (Pregnyl, Organon) | — | Use 10 or more days after onset of estrus to induce ovulation and prevent hyperestrogenemia; repeat in 1-2 wk prn |
50-100 U/animal IM14 | ||
200-1000 U/animal IM52 | ||
Hydrocortisone sodium succinate | 25-40 mg/kg IV52 | Shock |
Hydrogen peroxide (3%) | 2.2 mL/kg PO52 | Emetic |
Hydroxyzine (Atarax, Roerig) | 2 mg/kg PO q8h52 | Antihistamine; pruritus; may cause drowsiness |
Insulin, glargine | 0.5 U SC q12h23 | |
Insulin, NPH | 0.1 U/animal SC q12h52 | |
0.5-1 U/kg (or to effect) SC49 | Diabetes mellitus; diabetic ketoacidosis; monitor blood glucose | |
Insulin, ultralente | 0.1 U/animal SC q24h52 | Diabetes mellitus; monitor blood glucose |
Interferon-α | 107 units IV or intranasal q24h for several days31 | Adjunctive therapy for influenza |
Iohexol | 0.25-0.5 mL injected epidurally at the L5-L6 intervertebral disc space/kg3 | Myelography |
10 mL/kg PO52 | Gastrointestinal contrast study; can dilute 1:1 with water | |
2.3 mL/kg IV66 | Excretory urography | |
Ipecac (7%) | 2.2-6.6 mL/animal PO52 | Emetic |
Iron dextran | 10 mg/animal IM once49 | Iron deficiency anemia; hemorrhage |
Isotretinoin | 2 mg/kg PO q24h4 | Cutaneous epitheliotropic lymphoma |
Kaolin/pectin | 1-2 mL/kg PO q2-6h prn52 | Gastrointestinal protectant |
Lactulose syrup (Cephulac, Merrill Dow) | 0.15-0.75 mL/kg PO q12h52 150-175 mg/kg PO q8-12h25 |
Absorption of blood ammonia in hepatic disease; may cause soft stools at higher dose |
L-asparaginase | 400 U/kg SC, IM4 | Antineoplastic |
10,000 U/m2 SC q7d × 3 treatments47 | Part of a noninvasive chemotherapy protocol | |
Levothyroxine | 50-100 μg/animal q12h72 | Hypothyroidism |
Loperamide | 0.2 mg/kg PO q12h52 | Antidiarrheal |
Mannitol | 0.5-1 g/kg IV3 | Give over 20 min |
Methotrexate | 0.5 mg/kg IV4 | Antineoplastic |
0.8 mg/kg IM47 | Part of noninvasive protocol for treatment of lymphomaa | |
Metoclopramide | 0.2-1 mg/kg PO, SC, IM q6-8h53 | Antiemetic; motility enhancer |
Milk thistle (Silybum marianum) | 4-15 mg/kg PO q8-12h25 | Hepatoprotective |
Misoprostol (Cytotech, Searle) | 1-5 μg/kg PO q8h52 | Gastric ulcers |
Nandrolone decanoate | 1-5 mg/kg IM q7d52 | Anabolic steroid |
Nutri-Cal (EVSCO) | 1-3 mL/animal PO q6-8h52 | Nutritional supplement |
Octreotide (Sandostatin, Novartis) | 1-2 μg/kg SC q8-12h49 | Somatostatin analogue; potential treatment for insulinomas |
Omeprazole (Prilosec, Astra Merck) | 0.7 mg/kg PO q24h17 | Proton-pump inhibitor; decreases gastric secretion of HCl |
4 mg/kg PO q24h25 | Helicobacter; use with clarithromycin and metronidazole | |
Ondansetron | 1 mg/kg PO q12-24h49 | Antiemetic |
Oseltamivir phosphate (Tamiflu, Genentech) | 5-10 mg/kg PO q12h × 10 days31 | Antiviral for influenza treatment |
Oxytocin | 0.2-3 U/kg SC, IM52 | Expels retained fetuses; stimulates lactation |
Penicillamine | 10 mg/kg PO q24h25 | Copper toxicity |
Pentoxifylline (Pentoxil, Upsher-Smith) | 20 mg/kg PO q12h37 | Improves perfusion to hypoperfused tissue by increasing deformability of erythrocytes; supportive treatment for ferret systemic coronavirus |
Pet-Tinic (SmithKline) | 0.2 mL/kg PO q24h52 | Nutritional/iron supplement for anemia |
Phenobarbital | 1-2 mg/kg PO q8-12h39,52 | Seizure control |
2-10 mg/kg/h IV constant-rate infusion3 | Seizure control if diazepam is not effective | |
Phenoxybenzamine (Dibenzyline, SmithKline Beecham) | 3.75-7.5 mg/animal PO q24-72h59 |
α-Adrenergic antagonist; smooth muscle relaxation for urethral obstruction; potential gastrointestinal or cardiovascular side effects |
Polyprenol (Vetimmune, Sass & Sass) | 3 mg/kg PO 3 ×/wk37 | Antioxidant and immunostimulant; supportive treatment for ferret systemic coronavirus |
Potassium bromide | — | Seizure control |
22-30 mg/kg q24h PO3 | Dose if used with phenobarbitol | |
70-80 mg/kg q24h PO3 | Dose if used alone | |
Prazosin (Minipress, Zoetis) | 0.05-0.1 mg/kg PO q8h59 | α-Adrenergic antagonist; smooth muscle relaxation for urethral obstruction; potential for gastrointestinal and cardiovascular side effects |
Prednisone | 0.25 mg/kg PO q12h × 5 days, then 0.1 mg/kg q12h × 10 days52 | Postoperative adrenalectomy; after initial dose of dexamethasone |
0.25-1 mg/kg PO divided q12h52 | Insulinoma; gradually increase to 4 mg/kg/day prn; up to 2 mg/kg/day when given with diazoxide | |
0.5 mg/kg PO q12h × 7-10 days, then q24h × 7-10 days, then q48h × 7-10 days52 | Postoperative adrenalectomy | |
1 mg/kg PO q24h × 7-14 days52 | Use following heartworm adulticide treatment; thromboembolism | |
1.25-2.5 mg/kg PO q24h52 | Eosinophilic gastroenteritis; treat until clinical signs abate; gradually decrease to q48h | |
1.5 mg/kg PO q24h × 7 days, then taper to 0.8 mg/kg PO q24h46 | Management of eosinophilic gastroenteritis | |
2 mg/kg PO q24h52 | Palliative therapy for lymphosarcomaa or chronic inflammatory bowel disease; taper dose as able | |
Procarbazine | 50 mg/m2 PO q24h × 14 days4 | Part of a noninvasive protocol for treatment of lymphomaa |
Proligestone | 50 mg SC59 | Induce ovulation when jill has been in estrus for 10 days; not available in the United States |
Prostaglandin F2-α (Lutalyse, Upjohn) | 0.1-0.5 mg/animal IM prn7 | Metritis; expels necrotic debris |
0.5 mg/animal IM7 | Can induce delivery on day 41 if only one kit; follow with 6 U oxytocin 1-4 hr later | |
Pyridostigmine (Mestinon, Valeant) | 1 mg/kg PO q8h13 | Oral cholinesterase inhibitor for potential treatment of myasthenia gravis |
1 mg/kg PO q8-12h2 | Myasthenia gravis; overdose possible with long-term use | |
Ranitidine bismuth citrate (Pylorid, Glaxo Wellcome) | 24 mg/kg PO q8h44 | Helicobacter; use in combination with clarithromycin; not available in the United States |
Ranitidine HCl (Zantac, Glaxo Wellcome) | 3.5 mg/kg PO q12h25,66 | Inhibits acid secretion; gastrointestinal ulcers |
S-adenosylmethionine (SAMe) (Vetri-SAMe, Vetriscience Labs) | 20-100 mg/kg PO q24h49 | Adjunctive treatment for liver disease; hepatoprotectant; improves synthesis of glutathione and other compounds important for liver function |
Saw palmetto | 0.15 mL/animal PO q12h52 | Homeopathic remedy used for dysuria associated with prostatic enlargement |
Stanozolol (Winstrol, Upjohn) | 0.5 mg/kg PO, SC q12h52 | Anemia; anabolic steroid; use with caution in hepatic disease |
Sucralfate (Carafate, Hoechst Marion Roussel) | 25-125 mg/kg PO q8-12h52 | Gastrointestinal ulcers; give before meals; requires acidic pH |
Sulfasalazine | 62.5-125 mg PO q8-24h49 | Management of colitis |
Theophylline elixir | 4.25 mg/kg PO q8-12h52 | Bronchodilator |
Thyroid-stimulating hormone (TSH) | 1 U IV30 | Blood for T4 measurement taken 120 min later |
Thyroxine | 0.2-0.4 mg/kg q12h52 | Hypothyroidism; adjust and taper as needed |
Trientine (Syprine, Valeant) | 10 mg/kg PO q12h25 | Chelating agent used for copper toxicosis |
Ursodiol (Actigall, Ciba) | 15 mg/kg PO q12h9 | Treatment of chronic hepatopathies |
Vincristine | 0.12-0.2 mg/kg IV4 | |
0.75 mg/m2 IV4 | Minimal myelosuppression | |
Vitamin A (retinol palmitate) | 50,000 U IM q24h × 2 treatments62 | Reduced mortality secondary to canine distemper virus infection |
Vitamin B complex | 1-2 mg/kg IM prn52 | Dose based on thiamine content |
Vitamin C | 50-100 mg/kg PO q12h25 | Adjunct therapy for lymphoma |
Vitamin K | 2.5 mg/kg SC, then 1-2.5 mg/kg PO divided q8-12h × 5-7 days49 | First generation rodenticide toxicity (e.g., warfarin class) |
5 mg/kg SC, then 2.5 mg/kg PO divided q8-12h × 3 wk49 | Second generation rodenticide toxicity (e.g., brodifacoum class) |
|
2.5-5 mg/kg SC, then 2.5 mg/kg PO divided q8-12h × 3-4 wk49 | Inandione or unknown anticoagulant toxicity | |
Yeast, brewer’s | - tsp PO q12h52 | Source of chromium to stabilize glucose and insulin for animals with insulinomas |
Zanamivir (Relenza, GlaxoSmithKline) | 12.5 mg/kg intranasal only5 | Antiviral for influenza treatment; greater effect if used with amantadine |
0.3-1 mg/kg via inhalation q12h31 |
See Table 11-13 for chemotherapy protocols for lymphoma.
Table 11-8.
Measurements | Female | Male |
---|---|---|
Hematologya | ||
PCV (%) | 34.6-55 | 33.6-61 |
RBC (106/μL) | 6.77-9.76 | 7.1-13.2 |
Hgb (g/dL) | 11.9-17.4 | 12-18.5 |
MCV (fL) | 44.4-53.7 | 42.6-52.5 |
MCH (pg) | 16.4-19.4 | 13.7-19.7 |
MCHC (g/dL) | 33.2-42.2 | 30.3-34.9 |
WBC (103/μL) | 2.5-18.2 | 4.4-19.1 |
|
12-84 | 11-82 |
|
0-4.2 | 0-2.2 |
|
12-95 | 12-73 |
|
1-8 | 0-9 |
|
0-9 | 0-8.5 |
|
0-2.9 | 0-2.7 |
|
264-910 | 297-730 |
|
2-14 | 1-12 |
Biochemistries | ||
ALP (U/L) | 3-62 | 11-120 |
ALT (U/L) | 54-280 | 54-289 |
AST (U/L) | 40-120 | 28-248 |
Bilirubin, total (mg/dL) | 0-1 | 0-0.1 |
Bile acids (μmol/L) | 0.0-28.9 | 0.0-28.9 |
BUN (mg/dL) | 10-45 | 11-42 |
Calcium (mg/dL) | 8-10.2 | 8.3-11.8 |
Carbon dioxide (mEq/L) | 16.5-27.8 | 12.2-28 |
Chloride (mEq/L) | 112-124 | 102-126 |
Cholesterol (mg/dL) | 122-296 | 64-221 |
Creatinine (mg/dL) | 0.2-1 | 0.2-1 |
GGT (U/L) | 0-5 | 0-5 |
Glucose (mg/dL) | 85-207 | 62.5-198 |
LDH (U/L) | — | 241-752 |
Lipase (U/L) | — | 0-200 |
Phosphorus (mg/dL) | 4.2-10.1 | 4-8.7 |
Potassium (mEq/L) | 4.2-7.7 | 4.1-7.3 |
Protein, total (g/dL) | 5.1-7.2 | 5.3-7.4 |
|
3.2-4.1 | 2.8-4.2 |
|
2.2-3.2 | 2-4 |
|
1-1.6 | 0.8-2.1 |
Sodium (mEq/L) | 142-156 | 137-162 |
Triglycerides (mg/dL) | — | 10-32 |
Several of these hematology values were obtained from ferrets under isoflurane anesthesia. This can artificially lower red cell indices and may be responsible for the wide ranges in some values.
Table 11-9.
Protein Electrophoresis Values for Ferrets.48
Parameter | Normal Values |
---|---|
Total protein (g/dL) | 5.6-7.2 |
Albumin (g/dL) | 3.3-4.1 |
Alpha1 globulins (g/dL) | 0.33-0.56 |
Alpha2 globulins (g/dL) | 0.36-0.60 |
Beta globulins (g/dL) | 0.83-1.2 |
Gamma globulins (g/dL) | 0.3-0.8 |
A/G | 1.3-2.1 |
Table 11-10.
Parameter | Normal Values |
---|---|
Adult body weight, male | 1-2 kg |
Adult body weight, female | 0.65-0.95 kg |
Birth weight | 6-12 g |
Weight at 7 days | 30 g average |
Weight at 14 days | 60-70 g |
Sexual maturity | 6-12 mo (usually 1st spring after birth) |
Reproductive cycle | Induced ovulator |
Gestation period | 42 ± 2 days |
Litter size | 1-18 (average 8, primiparous jill 10) |
Weaning age | 6-8 wk |
Eyes open | 34 days |
Hearing | 32 days |
Life span | 5-9 yr (average in United States) |
Food consumption | 43 g/kg/day |
Water consumption | 75-100 mL/day |
Gastrointestinal transit time | 3-4 hr |
Enteral feeding requirements | 2000-3000 kcal/kg/day |
Dental formula | 2(I 3/3 C 1/1 P 3/3 M 1/2) = 34 |
Deciduous teeth erupt | 20-28 days |
Permanent teeth erupt | 50-74 days |
Canines erupt | 50 days |
Molars erupt (first to fourth) | 53-74 days |
Heart rate | 200-400 beats/min |
Mean systolic blood pressure | 133-161 mmHg |
Respiratory rate | 33-36 breaths/min |
Rectal temperature | 37.8-40°C (100-104°F) |
Blood volume | 60-80 mL (5%-7% body weight) |
Intraocular pressure | 22.8 ± 5.5 mmHg |
Endotracheal tube size | 2-4 mm ID |
Prothrombin time (PT) | 8-16.5 sec |
Partial thromboplastin time (PTT) | 16-25 sec |
Table 11-11.
Urinalysis Values of Ferrets.52
Parameter | Male | Female |
---|---|---|
Volume (mL/24 hr) | 26 (8-48) | 28 (8-140) |
Sodium (mmol/24 hr) | 1.9 (0.4-6.7) | 1.5 (0.2-5.6) |
Potassium (mmol/24 hr) | 2.9 (1-9.6) | 2.1 (0.9-5.4) |
Chloride (mmol/24 hr) | 2.4 (0.7-8.5) | 1.9 (0.3-7.8) |
pH | 6.5-7.5a | 6.5-7.5a |
Protein (mg/dL) | 7-33 | 0-32 |
Exogenous creatinine clearance (mL/min/kg)b | — | 3.32 ± 2.16 |
Insulin clearance (mL/min/kg) | — | 3.02 ± 1.78 |
Specific gravity | 1.040-1.052 | __ |
Urine pH can vary according to diet; normal urine pH in ferrets on a high-quality, meat-based diet is approximately 6.
Endogenous creatinine clearance (mL/min/kg) = 2.5 ± 0.93.
Table 11-12.
Age | Recommendation |
---|---|
4-6 wk | CDVa vaccination if dam is unvaccinated |
6-8 wk | CDVa,b vaccination if dam was vaccinated; physical examination; fecal examination |
10-11 wk | CDVa, b, c vaccination; physical examination; fecal examination |
12-14 wk | CDVa, b, c vaccination; rabies vaccination;d physical examination; fecal examination (optional) |
4-8 mo | Spay/castrate; fecal examination; remove musk glands (optional); start heartworm and flea prevention (endemic areas) |
1 yr | CDVa,e booster; rabies booster;d physical examination; dental prophylaxis and fecal examination if indicated; CBC; heartworm and flea prevention |
2 yr | CDVa,e,f booster; rabies booster;d physical examination; dental prophylaxis and fecal examination if indicated; CBC; heartworm and flea prevention |
3 yr and older (every 6 mo) | CDVa,e,f booster (annual); rabies boosterd (annual); physical examination; dental prophylaxis and fecal examination if indicated; CBC; serum chemistries, including fasting blood glucose; heartworm and flea prevention |
CDV, canine distemper vaccine; Purevax (Merial) is the only CDV approved for use in ferrets; if Purevax is unavailable, other vaccines which have been used include Novibac DPv (Merck) and Recombitek (Merial).
Purevax is recommended to be administered at 8 wk, then every 3 wk for 3 doses.
Vaccinations are generally administered at 2-3 wk intervals until the ferret is 12-14 wk of age.
Only a killed virus vaccine (Imrab 3, Rhône Merieux) should be used. Vaccines should be separated by several days to reduce vaccine reactions.
In previously unvaccinated adults, an initial series of two vaccinations given 14-28 days apart should be given.
Rabies and distemper titers are under evaluation and may alter the revaccination schedule of older animals.
Table 11-13.
Chemotherapy Protocols for Lymphoma in Ferrets.a
Protocol I47,52 | |||
---|---|---|---|
Week | Day | Agent | Dosage |
1 | 1 | Prednisone | 1-2 mg/kg PO q12h and continued throughout therapy |
1 | Vincristine | 0.025 mg/kg IV | |
3 | Cyclophosphamide | 10 mg/kg PO, SC | |
2 | 8 | Vincristine | 0.025 mg/kg IV |
3 | 15 | Vincristine | 0.025 mg/kg IV |
4 | 22 | Vincristine | 0.025 mg/kg IV |
24 | Cyclophosphamide | 10 mg/kg PO, SC | |
7 | 46 | Cyclophosphamide | 10 mg/kg PO, SC |
9 | 63 | Prednisone | Gradually decrease dose to 0 over the next 4 wk |
Protocol IIb,52 | ||
---|---|---|
Week | Agent | Dosage |
1 | Vincristine | 0.025 mg/kg IV |
L-asparaginase | 400 U/kg IP | |
Prednisone | 1 mg/kg PO q24h and continued throughout therapy | |
2 | Cyclophosphamide | 10 mg/kg SC |
3 | Doxorubicin | 1 mg/kg IV |
4-6 | As weeks 1-3 above, but discontinue L-asparaginase | — |
8 | Vincristine | 0.025 mg/kg IV |
10 | Cyclophosphamide | 10 mg/kg SC |
12 | Vincristine | 0.025 mg/kg IV |
14 | Methotrexate | 0.5 mg/kg IV |
Protocol III47 | ||
---|---|---|
Week | Agent | Dosage |
1 | L-asparaginase | 10,000 U/m2 SC |
Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) | |
Prednisone | 2 mg/kg PO daily for 7 days, then q48h throughout therapy | |
2 | L-asparaginase | 10,000 U/m2 SC |
Perform CBCc | ||
3 | L-asparaginase | 10,000 U/m2 SC |
Cytosar | 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H20) | |
4 | Perform CBCc | |
5 | Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) |
7 | Methotrexate Perform CBCc | 0.8 mg/kg IM |
8 | Perform CBCc | |
9 | Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) |
11 | Cytosar | 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H2O) |
Leukeran | 1 tablet/animal PO or ½ tablet/animal PO × 2 days | |
12 | Perform CBCc | |
13 | Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) |
15 | Procarbazine | 50 mg/m2 PO q24h × 14 days |
16 | Perform CBCc | |
17 | Perform CBCc | |
18 | Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) |
20 | Cytosar | 300 mg/m2 SC × 2 days (dilute 100 mg with 1 mL H2O) |
Leukeran | 1 tablet/animal PO or ½ tablet/animal PO × 2 days | |
23 | Cytoxin | 250 mg/m2 PO, SC (in 50 mL/kg of NaCl SC) |
26 | Procarbazine | 50 mg/m2 PO q24h × 14 days |
27 | Perform CBCc and chemistry panel | If not in remission, continue weeks 20-26 for 3 cycles |
Protocol IV4 | ||
---|---|---|
Week | Agent | Dosage |
3 days | L-asparaginase | 400 U/kg SC (premedicate with diphenhydramine) |
1 | Vincristine | 0.12 mg/kg IV |
Prednisone | 1 mg/kg PO q24h continue throughout therapy | |
Cyclophosphamide | 10 mg/kg PO | |
2 | Vincristine | 0.12 mg/kg IV |
3 | Vincristine | 0.12 mg/kg IV |
4 | Vincristine | 0.12 mg/kg IV |
Cyclophosphamide | 10 mg/kg PO | |
7, 10, 13, etc. | Vincristine | 0.12 mg/kg IV |
Cyclophosphamide | 10 mg/kg PO | |
Continue therapy every 3 wk for 1 yr, then decrease to every 4-6 wk | ||
Rescue treatment | Doxorubicin | 1-2 mg/kg IV (over 20 min) |
CBC should be checked weekly during therapy; after therapy is discontinued, continue to monitor CBC and do physical examination at 3-mo intervals.
Protocol is continued in sequence biweekly after week 14, making the therapy protocol less intensive.
If CBC shows severe myelosuppression, reduce dosage by 25% for all subsequent treatments of the previously used myelosuppressive drug.
Table 11-14.
Conversion of Body Weight (kg) to Body Surface Area (m2).47
Body Weight (kg) | Body Surface Area (m2) |
---|---|
0.5 | 0.063 |
0.6 | 0.071 |
0.7 | 0.079 |
0.8 | 0.086 |
0.9 | 0.093 |
1.0 | 0.100 |
1.1 | 0.107 |
1.2 | 0.113 |
1.3 | 0.119 |
1.4 | 0.125 |
1.5 | 0.131 |
1.6 | 0.137 |
1.7 | 0.142 |
1.8 | 0.148 |
1.9 | 0.153 |
2.0 | 0.159 |
2.1 | 0.164 |
2.2 | 0.169 |
2.3 | 0.174 |
2.4 | 0.179 |
2.5 | 0.184 |
References
- 1.Antinoff N. Neoplasia in ferrets. In: Bonagura J.D., editor. Kirk’s Current Veterinary Therapy XIII: Small Animal Practice. WB Saunders Co; Philadelphia: 2000. pp. 1149–1152. [Google Scholar]
- 2.Antinoff N. Diagnosis and successful treatment of myasthenia gravis in a ferret. ExoticsCon. 2015;367 [Google Scholar]
- 3.Antinoff N., Giovanella C.J. Musculoskeletal and neurologic diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 132–140. [Google Scholar]
- 4.Antinoff N., Hahn K. Ferret oncology. Vet Clin North Am Exot Anim Pract. 2004;7:579–626. doi: 10.1016/j.cvex.2004.05.001. [DOI] [PubMed] [Google Scholar]
- 5.Barron H.W., Rosenthal K.L. Respiratory diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 78–85. [Google Scholar]
- 6.Beaufrère H., Neta M., Smith D.A. Demodectic mange associated with lymphoma in a ferret. J Exot Pet Med. 2009;18:57–61. [Google Scholar]
- 7.Bell J.A. Periparturient and neonatal diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 2nd ed. WB Saunders Co; St. Louis: 2004. pp. 50–57. [Google Scholar]
- 8.Bennett K.R., Gaunt M.C., Parker D.L. Constant rate infusion of glucagon as an emergency treatment for hypoglycemia in a domestic ferret (Mustela putorius furo) J Am Vet Med Assoc. 2015;246:451–454. doi: 10.2460/javma.246.4.451. [DOI] [PubMed] [Google Scholar]
- 9.Burgess M., Garner M. Clinical aspects of inflammatory bowel disease in ferrets. Exot DVM. 2002;4(2):29–34. [Google Scholar]
- 10.Carpenter J.W. 2017. Personal observation. [Google Scholar]
- 11.Chen S., Michels D., Culpepper E. Nonsurgical management of hyperadrenocorticism in ferrets. Vet Clin Exot Anim. 2014;17:35–49. doi: 10.1016/j.cvex.2013.09.001. [DOI] [PubMed] [Google Scholar]
- 12.Coburn D.R., Morris J.A. The treatment of Salmonella typhimurium infection in ferrets. Cornell Vet. 1949;39:198. [Google Scholar]
- 13.Couturier J., Huynh M., Boussarie D. Autoimmune myasthenia gravis in a ferret. J Am Vet Med Assoc. 2009;235:1462–1466. doi: 10.2460/javma.235.12.1462. [DOI] [PubMed] [Google Scholar]
- 14.Fisher M., Beck W., Hutchinson M.J. Efficacy and safety of selamectin (Stronghold®/RevolutionTM) used off-label in exotic pets. Intern J Appl Res Vet Med. 2007;5:87–96. [Google Scholar]
- 15.Fox J.G., Bell J.A. Diseases of the genitourinary system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 335–361. [Google Scholar]
- 16.Fox J.G., Lee A. The role of Helicobacter species in newly recognized gastrointestinal diseases of animals. Lab Anim Sci. 1997;47:222–227. [PubMed] [Google Scholar]
- 17.Fox J.G., Marini R.P. Helicobacter mustelae infection in ferrets: pathogenesis, epizootiology, diagnosis, and treatment. Semin Avian Exot Pet Med. 2001;10:36–44. [Google Scholar]
- 18.Giral M., Garcia-Olma D.C., Gomez-Juarez M. Anaesthetic effect in the ferret of alfaxalone alone and in combination with medetomidine or tramadol: a pilot study. Lab Anim. 2014;48:313–320. doi: 10.1177/0023677214539150. [DOI] [PubMed] [Google Scholar]
- 19.Greenacre C.B. Incidence of adverse events in ferrets vaccinated with distemper or rabies vaccine: 143 cases (1995-2001) J Am Vet Med Assoc. 2003;223:663–665. doi: 10.2460/javma.2003.223.663. [DOI] [PubMed] [Google Scholar]
- 20.Greenacre C.B., Dowling M., Nobrega-Lee M. Histoplasmosis in a group of domestic ferrets (Mustela putorius furo) ExoticsCon. 2015;363 [Google Scholar]
- 21.Hawkins M.G. Advances in exotic mammal clinical therapeutics. Vet Clin N Am Exot Anim Pract. 2015;18:323–327. doi: 10.1016/j.cvex.2015.01.008. [DOI] [PubMed] [Google Scholar]
- 22.Hein J., Spreyer F., Sauter-Louis C. Reference ranges for laboratory parameters in ferrets. Vet Rec. 2012;171:218. doi: 10.1136/vr.100628. [DOI] [PubMed] [Google Scholar]
- 23.Hess L. Insulin glargine treatment of a ferret with diabetes mellitus. J Am Vet Med Assoc. 2012;241:1490–1494. doi: 10.2460/javma.241.11.1490. [DOI] [PubMed] [Google Scholar]
- 24.Hoppes S.M. The senior ferret. Vet Clin North Am Exot Anim Pract. 2010;13:107–121. doi: 10.1016/j.cvex.2009.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Jepson L. Ferrets. In: Jepson L., editor. Exotic Animal Medicine: A Quick Reference Guide. 2nd ed. Elsevier; St. Louis: 2016. pp. 1–42. [Google Scholar]
- 26.Johnson D. Current therapies for ferret adrenal disease. Proc Atlantic Coast Vet Conf. 2006:1–7. [Google Scholar]
- 27.Johnson-Delaney C. Ferrets: anaesthesia and analgesia. In: Keeble E., Meredith A., editors. BSAVA Manual of Rodents and Ferrets. British Small Animal Veterinary Association; Gloucester, UK: 2009. pp. 245–253. [Google Scholar]
- 28.Johnson-Delaney C.A. CRC Press; Boca Raton: 2017. Ferret Medicine and Surgery; pp. 457–467. [Google Scholar]
- 29.Katzenbach JE, Wittenburg LA, Allweiler SI, et al. Pharmacokinetics of single-dose buprenorphine, butorphanol, and hydromorphone in the domestic ferret (Mustela putorius furo). J Exot Pet Med. In press.
- 30.Keeble E. Endocrine diseases in small mammals. In Pract. 2001;23:570–585. [Google Scholar]
- 31.Kiupel M., Perpinan D. Viral diseases of ferrets. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 439–517. [Google Scholar]
- 32.Ko J.C., Marini R.P. Anesthesia. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 259–283. [Google Scholar]
- 33.Ko J.C., Heaton-Jones T.G., Nicklin C.F. Comparison of sedative and cardiorespiratory effects of diazepam, acepromazine, and xylazine in ferrets. J Am Anim Hosp Assoc. 1998;34:234–241. doi: 10.5326/15473317-34-3-234. [DOI] [PubMed] [Google Scholar]
- 34.Ko J.C., Nicklin C.F., Montgomery T. Comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-xylazine and tiletamine-zolazepam-xylazine-butorphanol in ferrets. J Am Anim Hosp Assoc. 1998;34:164–174. doi: 10.5326/15473317-34-2-164. [DOI] [PubMed] [Google Scholar]
- 35.Kraus M.S., Morrisey J.K. Cardiovascular and other diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 62–77. [Google Scholar]
- 36.Larsen K.S., Siggurdsson H., Mencke N. Efficacy of imidacloprid, imidacloprid/permethrin and phoxim for flea control in the Mustelidae (ferrets, mink) Parasitol Res. 2005;97:S107–S112. doi: 10.1007/s00436-005-1453-0. [DOI] [PubMed] [Google Scholar]
- 37.Lennox A. GI disease in ferrets. Available at: https://www.cliniciansbrief.com/article/gi-disease-ferrets. Published Sept 2013. Accessed May 25, 2017.
- 38.Lennox A. Alternative surgical options for elective altering in exotic companion mammals. ExoticsCon. 2015:435–444. [Google Scholar]
- 39.Lewington J.H. Appendix. In: Lewington J.H., editor. Ferret Husbandry, Medicine and Surgery. Butterworth Heinemann; Oxford: 2000. pp. 273–282. [Google Scholar]
- 40.Longley L. Ferret anaesthesia. In: Longley L., editor. Anaesthesia of Exotic Pets. Saunders/Elsevier; Philadelphia: 2008. pp. 85–95. [Google Scholar]
- 41.Malik R., Martin P., McGill J. Successful treatment of invasive nasal cryptococcosis in a ferret. Aust Vet J. 2000;78:158–159. doi: 10.1111/j.1751-0813.2000.tb10582.x. [DOI] [PubMed] [Google Scholar]
- 42.Malka S., Hawkins M.G., Zabolotzky S.M. Immune-mediated pure red cell aplasia in a domestic ferret. J Am Vet Med Assoc. 2010;237:695–700. doi: 10.2460/javma.237.6.695. [DOI] [PubMed] [Google Scholar]
- 43.Marini R.P. Physical examination, preventive medicine, and diagnosis in the ferret. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 235–258. [Google Scholar]
- 44.Marini R.P., Fox J.G., Taylor N.S. Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. Am J Vet Res. 1999;60:1280–1286. [PubMed] [Google Scholar]
- 45.Marini R.P., Ryden E.B., Rosenblad W.D. Functional islet cell tumor in six ferrets. J Am Vet Med Assoc. 1993;202:430–433. [PubMed] [Google Scholar]
- 46.Maurer K.J., Fox J.G. Diseases of the gastrointestinal system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 363–375. [Google Scholar]
- 47.Mayer J., Erdman S.E., Fox J.G. Diseases of the hematopoietic system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 311–334. [Google Scholar]
- 48.Melillo A. Applications of serum protein electrophoresis in exotic mammals. Vet Clin North Am Exot Anim Pract. 2013;16:211–225. doi: 10.1016/j.cvex.2012.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Meredith A. 9th ed. Gloucester; British Small Animal Veterinary Association: 2015. Small Animal Formulary—Part B: Exotic Pets. [Google Scholar]
- 50.Miller D.S., Eagle R.P., Zabel S. Efficacy and safety of selamectin in the treatment of Otodectes cynotis infestation in domestic ferrets. Vet Rec. 2006;159:748. doi: 10.1136/vr.159.22.748. [DOI] [PubMed] [Google Scholar]
- 51.Morrisey J.K. Ferrets: therapeutics. In: Keeble E., Meredith A., editors. BSAVA Manual of Rodents and Ferrets. British Small Animal Veterinary Association; Gloucester, UK: 2009. pp. 237–244. [Google Scholar]
- 52.Morrisey J.K. Ferrets. In: Carpenter J.W., editor. Exotic Animal Formulary. 4th ed. Elsevier Saunders; St. Louis: 2013. pp. 560–594. [Google Scholar]
- 53.Morrisey J.K., Carpenter J.W. Formulary. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 566–575. [Google Scholar]
- 54.Neuwirth L., Isaza R., Bellah J. Adrenal neoplasia in seven ferrets. Vet Radiol Ultrasound. 1993;34:340–346. [Google Scholar]
- 55.Patterson M.M., Kirchain S.M. Comparison of three treatments for control of ear mites in ferrets. Lab Anim Sci. 1999;49:655–657. [PubMed] [Google Scholar]
- 56.Patterson M.M., Fox J.C., Eberhard M.L. Parasitic diseases. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 553–572. [Google Scholar]
- 57.Perpinan D., Ramis A., Tomas A. Outbreak of canine distemper in domestic ferrets (Mustela putorius furo) Vet Rec. 2008;163:246–250. doi: 10.1136/vr.163.8.246. [DOI] [PubMed] [Google Scholar]
- 58.Pinon C., Huynh M. Flexible gastrointestinal endoscopy in ferrets. ExoticsCon. 2015:459–463. doi: 10.1016/j.cvex.2015.05.002. [DOI] [PubMed] [Google Scholar]
- 59.Pollock C.G. Disorders of the urinary and reproductive systems. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 46–61. [Google Scholar]
- 60.Powers L.V. Bacterial and parasitic diseases of ferrets. Vet Clin North Am Exot Anim Pract. 2009;12:531–561. doi: 10.1016/j.cvex.2009.06.001. [DOI] [PubMed] [Google Scholar]
- 61.Ramer J.C., Benson K.G., Morrisey J.K. Effects of melatonin administration on the clinical course of adrenocortical disease in domestic ferrets. J Am Vet Med Assoc. 2006;229:1743–1748. doi: 10.2460/javma.229.11.1743. [DOI] [PubMed] [Google Scholar]
- 62.Rodeheffer C., von Messling V., Milot S. Disease manifestations of canine distemper virus infection in ferrets are modulated by vitamin A status. J Nutr. 2007;137:1916–1922. doi: 10.1093/jn/137.8.1916. [DOI] [PubMed] [Google Scholar]
- 63.Rosenthal K.R., Wyre N.R. Endocrine diseases. In: Quesenberry K.E., Carpenter J.W., editors. Ferrets, Rabbits, and Rodents: Clinical Medicine and Surgery. 3rd ed. Saunders/Elsevier; St. Louis: 2012. pp. 86–102. [Google Scholar]
- 64.Sapienza J.S., Porcher D., Collins B.R. Tonometry in clinically normal ferrets (Mustela putorius furo) Prog Vet Comp Ophthalmol. 1991;1:291–294. [Google Scholar]
- 65.Schwarz L.A., Solano M., Manning A. The normal upper gastrointestinal examination in the ferret. Vet Radiol Ultrasound. 2003;44:165–172. doi: 10.1111/j.1740-8261.2003.tb01265.x. [DOI] [PubMed] [Google Scholar]
- 66.Silverman S., Tell L.A. Elsevier Saunders; St. Louis: 2005. Radiology of Rodents, Rabbits, and Ferrets: an Atlas of Normal Anatomy and Positioning. [Google Scholar]
- 67.Vella D. Cryptococcosis. In: Mayer J., Donnelly T.M., editors. Clinical Veterinary Advisor: Birds and Exotic Pets. Elsevier Saunders; St. Louis: 2013. p. 439. [Google Scholar]
- 68.Wagner R.A. Ferret cardiology. Vet Clin North Am Exot Anim Pract. 2009;12:115–134. doi: 10.1016/j.cvex.2008.09.001. [DOI] [PubMed] [Google Scholar]
- 69.Wagner R.A. Diseases of the cardiovascular system. In: Fox J.G., Marini R.P., editors. Biology and Diseases of the Ferret. 3rd ed. Wiley Blackwell; Ames: 2014. pp. 401–419. [Google Scholar]
- 70.Wagner R.A., Bailey E.M., Schneider J.F. Leuprolide acetate treatment of adrenocortical disease in ferrets. J Am Vet Med Assoc. 2001;218:1272–1274. doi: 10.2460/javma.2001.218.1272. [DOI] [PubMed] [Google Scholar]
- 71.Wagner R.A., Piche C.A., Jöchle W. Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease. Am J Vet Res. 2005;66:910–914. doi: 10.2460/ajvr.2005.66.910. [DOI] [PubMed] [Google Scholar]
- 72.Wyre N.R., Michels D., Chen S. Selected emerging diseases in ferrets. Vet Clin North Am Exot Anim Pract. 2013;16:469–493. doi: 10.1016/j.cvex.2013.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]